Johnson & Johnson (JNJ) said Monday it will present the latest data from the TAR-200 study to treat patients with Bacillus Calmette-Guerin-unresponsive, high-risk non-muscle-invasive bladder cancer with carcinoma in situ with or without papillary disease at the American Urological Association on April 26.
The 12-month duration of response findings from cohort 2 of the phase 2b trial evaluating the TAR-200 monotherapy revealed a positive complete response rate, according to a statement.
The company said it will also present the first results from cohort 4 of the phase 2b trial for patients with papillary-only, high-risk non-muscle invasive bladder cancer.
Price: 157.83, Change: +0.35, Percent Change: +0.23
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。